Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company that publicly describes itself as leveraging a proprietary technology platform to develop therapeutics with effective oral delivery. News about Lipocine often centers on clinical trial milestones, regulatory interactions, and partnering activity related to its oral drug candidates.
A key focus of recent news is LPCN 1154, an oral formulation of brexanolone in development for the potential treatment of postpartum depression (PPD). Company press releases highlight the initiation of a pivotal Phase 3 trial, first patient dosing, enrollment progress, interim safety reviews by an independent Data Safety Monitoring Board, and plans to use Phase 3 data to support a 505(b)(2) NDA submission. Updates also describe the outpatient design of the trial and its target population of women with severe PPD.
News flow also covers LPCN 2401, an oral proprietary anabolic androgen receptor agonist being evaluated in obesity‑related settings. Lipocine has reported Phase 2 clinical data showing changes in body composition and liver‑related measures in men with obesity and metabolic dysfunction associated steatohepatitis, and has presented these data at the ObesityWeek meeting. Additional releases discuss regulatory status and development plans for proof‑of‑concept studies.
Other recurring topics include LPCN 2101 for the potential treatment of epilepsy, with announcements about abstract acceptances and poster presentations at the American Epilepsy Society annual meeting, as well as corporate updates on financial results, TLANDO licensing and royalty revenue, and participation in investor conferences. Investors and observers can use the LPCN news stream to follow clinical progress, safety updates, licensing developments, and strategic communications that the company files or references in its SEC reports.
Lipocine has received FDA agreement to establish efficacy for LPCN 1154, an oral formulation for postpartum depression (PPD). The drug is based on brexanolone, with exposure similar to that seen in pregnant women. A pivotal pharmacokinetic (PK) bridge study is set for 4Q 2022, with results expected in 1Q 2023. This could lead to the first oral treatment option for PPD, addressing significant market needs. Lipocine's technology platform aims to create accessible therapies, potentially revolutionizing PPD treatment.
Lipocine (NASDAQ: LPCN) reported its Q2 2022 financial results with a net loss of $2.6 million, improving from a loss of $6.8 million in Q2 2021. Revenues were $0.5 million from a non-refundable fee related to LPCN 1111. R&D expenses rose to $2.9 million due to ongoing studies, including LPCN 1148 and LPCN 1154. The company has $37.4 million in cash as of June 30, 2022, down from $46.6 million at year-end 2021. Key developments include the launch of TLANDO™ and progress with FDA-approved studies for LPCN 1144 and LPCN 2101.
Lipocine Inc. (NASDAQ: LPCN) announced that the FDA has accepted its IND application for LPCN 2101, a neuroactive steroid aimed at treating epilepsy in adults. The company plans to initiate a Phase 2 study focusing on photosensitive epilepsy to assess safety and efficacy. Dr. Mahesh Patel emphasized the potential of LPCN 2101 in addressing unmet medical needs in epilepsy management, particularly for women of childbearing age.
LPCN 2101 has shown a favorable pharmacokinetic profile and no concerning safety signals in preclinical studies.
Lipocine Inc. (NASDAQ: LPCN) has been granted two new US patents by the USPTO: 11,337,987 for compositions treating CNS disorders, and 11,370,811 for testosterone dodecanoate compositions. These patents support Lipocine's innovative treatment programs for liver and CNS disorders, as stated by Dr. Mahesh Patel, the company’s CEO. Lipocine's pipeline includes TLANDO, LPCN 1144, and LPCN 1107, targeting conditions like hypogonadism and non-cirrhotic NASH.
Lipocine Inc. (NASDAQ: LPCN) presented its novel oral positive GABAA modulator for epilepsy, LPCN 2101, at the 2022 Epilepsy Foundation Pipeline Conference. This product aims to address the unique needs of women with epilepsy of childbearing age, whose treatment options are currently limited. Pending FDA clearance, a proof-of-concept study is planned for the second half of 2022. The conference focuses on advancements in epilepsy treatment and encourages potential collaborations.
Lipocine Inc. (NASDAQ: LPCN) announced positive results from its Open Label Extension (OLE) study for LPCN 1144, an oral testosterone prodrug. The study, involving 25 subjects over 72 weeks, showed LPCN 1144 was well tolerated, with no safety signals reported. Key liver injury markers like ALT and AST were significantly reduced and maintained during treatment. Additionally, liver histology improvements support further development of LPCN 1144 as a treatment for Nonalcoholic Steatohepatitis (NASH). The company plans to discuss pivotal study design with the FDA.
Lipocine Inc. (NASDAQ: LPCN) announced its Q1 2022 financial results with a net loss of $3.5 million, consistent with the previous year. R&D expenses rose to $1.9 million due to ongoing clinical studies for LPCN 1148 and related projects. General and administrative costs decreased to $1.2 million. The company maintains $42 million in cash and equivalents, down from $46.6 million at the end of 2021. TLANDO™ received FDA approval with a commercial launch expected in Q2 2022, while Phase 2 studies for LPCN 1148 and LPCN 1144 are progressing.
Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors on April 11, 2022. Dr. Jene brings over 20 years of biopharmaceutical experience, having facilitated over $6 billion in transactions. Dr. Papapetropoulos has a strong background in neuroscience and biopharmaceutical development. The company focuses on neuroendocrine and metabolic disorders, with a pipeline that includes products like TLANDO and LPCN 1148, targeting various conditions associated with testosterone deficiency and liver cirrhosis.
On March 29, 2022, Lipocine announced that its partner, Antares Pharma, received FDA approval for TLANDO™ (testosterone undecanoate), an oral testosterone replacement therapy for adult males with hypogonadism. This approval marks a significant milestone for Lipocine, which licensed the U.S. commercialization rights for TLANDO. The commercial launch is anticipated in Q2 2022, providing patients with a new, convenient treatment option. Lipocine continues to focus on developing innovative therapies for neuroendocrine and metabolic disorders while expanding its pipeline of drug candidates.
Lipocine Inc. (NASDAQ: LPCN) reported significant financial updates for the year ending December 31, 2021, including a net loss of $634,399, a reduction from a previous loss of $21 million. The company recognized $16.1 million in revenue, primarily from licensing fees related to TLANDO. R&D expenses decreased to $7.7 million, while general and administrative expenses fell to $5.3 million, mainly due to reduced legal and personnel costs. Lipocine also highlighted advancements in its clinical programs, including the initiation of a Phase 2 study for LPCN 1148 and an FDA-approved study for LPCN 1154.